Table 3.
Demographics by Patient
| No. | Demographics | Tumor Type (DDR Mutation) | No. of Prior Regimens | Best Response |
|---|---|---|---|---|
|
| ||||
| Dose Level 1: | ||||
|
| ||||
| 1 | White Male, Age 73 | Neuroendocrine prostate | >5 | PR |
| 2 | White Male, Age 44 | Colorectal (BRCA1) | 3 | PD |
| 3 | White Female, Age 50 | High grade neuroendocrine carcinoma | 1 | SD |
|
| ||||
| Dose Level 2: | ||||
|
| ||||
| 4 | Asian Male, Age 52 | Pancreatic | 3 | PD |
| 5 | White Male, Age 72 | High grade neuroendocrine carcinoma | 1 | SD |
| 6 | White Female, Age 50 | Adrenocortical carcinoma (p53/Li Fraumeni) | >5 | PD |
|
| ||||
| Dose Level 3 | ||||
|
| ||||
| 7 | White Female, Age 33 | Colorectal (BRCA1) | 4 | SD |
| 8 | Asian Female, Age 49 | Transformed SCLC | 2 | PR |
| 9 | White Male, Age 69 | Pancreatic (ATM) | 2 | SD |
| 10 | Asian Male, age 78 | SCLC | 2 | SD |
| 11 | White Male, age 71 | Neuroendocrine Prostate | 2 | SD* |
| 12 | Asian Female, Age 51 | SCLC | 3 | SD |
*
SD per RECIST, but with metabolic response on PET scan
DDR: DNA damage response; PR: partial response; SD: stable disease; PD: progressive disease; SCLC: small cell lung cancer. Best response is evaluated by response evaluation criteria in solid tumors version 1.1.